Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Value Of ¹⁸F-FDG PET/CT In Assessment Of Metabolic Response In Esophageal Cancer For Prediction Of Histopathological Response And Survival After Preoperative Chemoradiotherapy.

M. Mysliveček, Č. Neoral, R. Vrba, K. Vomáčková, J. Cincibuch, R. Formánek, P. Koranda, J. Zapletalova
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
AIM To evaluate the ability of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma. METHODS 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. (18)F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT. RESULTS PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months. CONCLUSION No statistically significant correlation was found between the (18)F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of (18)F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.
This paper references
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.
R. Downey (2003)
Cancer : Principles and Practice of Oncology
V. Devita (1982)
Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
B. M. Smithers (2008)
FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
S. Y. Song (2005)
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
P. Flamen (2002)
International variation
D. Parkin (2004)
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
K. Ott (2006)
The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
G. Couper (1998)
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
A. Mandard (1994)
Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
H. Kato (2002)
Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma.
D. Mcateer (1999)
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial
D. Girling (2002)
Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.
J. Luketich (1999)
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
M. K. Kim (2007)
Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma.
I. Brink (2004)
Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer
E. Levine (2006)
A phase II trial of preoperative one cycle of induction chemotherapy [capecitibine (CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients (pts) with resectable esophageal cancer
Sang Bae Kim (2005)
Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy.
B. Beseth (2000)
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
J. Lee (2004)
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
V. Gebski (2007)
Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians
T. G. Freedman (1997)
glucose - positron emission tomography ( 18 F - FDG - PET ) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer
SY Song
Cancer Statistics, 2005
A. Jemal (2005)
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
Pierre Rigo (2005)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
D. Cunningham (2006)
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.
S. Couban (2005)
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K. Becker (2003)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
F. Lordick (2007)
Survival of cancer patients in europe—The EUROCARE study
F. Pannelli (2004)
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
A. Berger (2005)
Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
G. Couper (1998)
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
W. Weber (2001)
[Cancer of the esophagus].
T. Watamuki (1970)
Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esopha
RJ Cerfolio (2008)
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
P. Flamen (2000)
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
I. Higuchi (2008)
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
T. Walsh (1996)
Cancer of the esophagus
R. BarreraCacicedo (1960)
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
M. Stahl (2005)
Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma.
W. Kneist (2004)
The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
R. Cerfolio (2005)
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
E. Heath (2000)
Improvement in staging of esophageal cancer with the addition of positron emission tomography.
M. Block (1997)
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
S. Urba (2001)
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
S. Swisher (2004)
Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
J. Port (2007)
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
B. Krause (2009)
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.
J. Bosset (1997)
Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy
D. Jones (1999)
A comparison of 18FDG PET and CT in the staging of oesophageal carcinoma
G Cook (1997)
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
B. Brücher (2001)
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
F. Flanagan (1997)
Esophageal cancer.
P. Enzinger (2003)
International variation. Oncogene 2004;23:6329-40
DM Parkin (2004)

This paper is referenced by
Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting the Early Response to Chemoradiotherapy of Advanced Esophageal Squamous Cell Carcinoma
Shunsuke Imanishi (2013)
Similarities and differences of neoadjuvant therapy among different sites of cancers
Zhai Haoran (2015)
Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma
R. Bütof (2019)
F ‐ fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy
P. Zhang ()
18F-FAMT-PET is useful for judging clinical complete response in advanced esophageal cancer patients who have received definitive chemoradiotherapy
M. Sohda (2017)
Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review.
J. Lu (2016)
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy
S. Chang (2016)
Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature
D. M. Voeten (2018)
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy
C. Xie (2019)
The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
Lihong Cong (2016)
The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma.
M. Schröer-Günther (2015)
Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
K. O’Sullivan (2015)
Expanding the role of positron emission tomography-computed tomography and its utility in the management of oesophageal cancer
Vinod Malik (2018)
Value of CT–PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma
J. A. Elliott (2014)
Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis.
D. J. de Gouw (2019)
Semantic Scholar Logo Some data provided by SemanticScholar